SCAN Group and SCAN Health Plan: Dr. Linda Rosenstock Elected Board Chair; Michael Plumb Appointed Chief Financial Officer

On Monday, November 2, 2020, SCAN Group, whose holdings include SCAN Health Plan, one of the nation’s largest not-for-profit Medicare Advantage plans, announced that Dr. Linda Rosenstock has been elected its new board chair and Michael Plumb has been named chief financial officer.

“Linda Rosenstock is committed both to public health and to addressing the social determinants of health that can play an outsize role in affecting outcomes,” continued Dr. Jain. “I’m confident she’ll provide SCAN with guidance and leadership as we seek out new and innovative partnerships not just to address illness, but to keep seniors healthy as they age.”

Rosenstock, who joined the SCAN board of directors in 2017, is dean emeritus of the UCLA Fielding School of Public Health.

Michael Plumb’s appointment as CFO will help SCAN develop new lines of business and expand its offerings to new communities. “With his deep knowledge of healthcare finance and Medicare Advantage, Michael is perfectly poised to play a leadership role in maintaining SCAN’s sound financial footing as well as in new business development and diversification,” said Jain.

Previously, Plumb served as Chief Financial Officer of CareMore Health and Aspire Health, divisions of Anthem Inc., where he worked closely with Jain to grow CareMore’s footprint from four to twelve U.S. states and, with the acquisition and integration of Aspire, to 32 states.

Last month, Jain sat down (virtually) with BioscienceLA CEO, Dave Whelan, for a fireside chat during the 2020 Los Angeles County Bioscience Forum, “Advancing Diversity & Equity.” Dr. Chandra Ford, PhD, the Founding Director of the UCLA Center for the Study of Racism, Social Justice and Health represented the UCLA Fielding School of Public Health by moderating a panel discussion on “Addressing Health Delivery Disparities, Laid Bare by COVID-19, in Underserved Communities.”

Previous
Previous

Protomer Gets a Boost to Develop Glucose Responsive Insulin

Next
Next

Congratulations to Keith Hoffman on joining Athos Therapeutics as its Chief Business Officer!